Gilead submits cobicistat NDA

Gilead Sciences Inc. (NASDAQ:GILD) submitted an NDA to FDA for cobicistat as a boosting agent for HIV treatment with protease inhibitors. The inhibitor of cytochrome P450 family 3 subfamily A ( CYP3A)...